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Abstract: Pediatric psoriasis consists broadly of 3 age groups of psoriatic patients: infantile 
psoriasis, a self-limited disease of infancy, psoriasis with early onset, and pediatric psoriasis 
with psoriatic arthritis. About one-quarter of psoriasis cases begin before the age of 18 years. 
A variety of clinical psoriasis types are seen in childhood, including plaque-type, guttate, 
erythrodermic, napkin, and nail-based disease. Like all forms of auto-immunity, susceptibility 
is likely genetic, but environmental triggers are required to initiate disease activity. The most 
common trigger of childhood is an upper respiratory tract infection. Once disease has occurred, 
treatment is determined based on severity and presence of joint involvement. Topical therapies, 
including corticosteroids and calcipotriene, are the therapies of choice in the initial care of 
pediatric patients. Ultraviolet light, acitretin and cyclosporine can clear skin symptoms, while 
methotrexate and etanercept can clear both cutaneous and joint disease. Concern for psycho-
logical development is required when choosing psoriatic therapies. This article reviews current 
concepts in pediatric psoriasis and a rational approach to therapeutics.
Keywords: psoriasis, autoimmunity, Streptococcus, etanercept, calcipotriene, topical 
corticosteroids
Introduction
Psoriasis vulgaris is a common dermatologic disorder seen in about 3.5% of the 
population.1 One-third of psoriasis cases in a dermatology center are pediatric.2 
Psoriasis is a T-cell mediated chronic inflammatory disorder of the skin characterized 
by hyper-proliferation of keratinocytes and consequent red scaly skin plaques. Pediatric 
onset psoriasis is somewhat different than adult disease, as pharyngitis, stress, and 
trauma are more common triggers of disease activity than in adulthood.3,4 Despite 
the differences in pediatric psoriasis, the therapies used for pediatric psoriasis are 
essentially the same as those used in adulthood, with dosage and strength reductions 
calculated based on age, weight, and available formulations. This article looks at a 
rational approach to the diagnosis and management of pediatric psoriasis, with a careful 
focus on those aspects of disease unique to the pediatric patient.
Demographics
About one-third of psoriasis vulgaris cases are seen in the pediatric age group.2 Most 
children manifest with plaque-type psoriasis vulgaris (68.6%) in similar patterns 
to adult patients, with lesions localized to the scalp, post auricular region, elbows, 
and knees. Guttate disease is more common in pediatric than adult patients, seen 
in 28.9% of 277 children in a Chinese survey. Other patterns can be observed in Therapeutics and Clinical Risk Management 2009:5 850
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childhood, including erythroderma (1.4%), pustular disease 
including palmoplantar pustular psoriasis (1.1%), and 
mucosal/glossitis can be observed as pediatric patterns of 
cutaneous psoriasis.5 Diaper involvement is very common in 
infancy, but involvement of the groin is uncommon in older 
children. Inverse psoriasis with involvement of the folds of 
the skin (axillae, inner thighs) represents a small minority 
of children. Additionally, nail psoriasis can be noted in the 
setting of plaque-type psoriasis vulgaris, psoriatic arthritis, 
or with isolated nail disease, the last sometimes being called 
trachyonychia, although this is controversial. Involvement 
of joints with psoriatic arthritis is less prevalent in younger 
patients; however, it does occur in childhood disease and 
should be considered in the differential of pediatric arthritis.4 
The annual incidence of psoriasis has been noted to have 
doubled from 1970 to 2000, but pediatric incidence has not 
been noted to be increasing.6 Psoriasis was not noted in a 
pediatric population survey of children aged 6 to 11 years in 
Taiwan, but in China the average age of pediatric psoriasis 
patients in China was noted to be 11 years, and median age 
of onset 10 years.5,7
Differences of onset between females and males have 
varied from study to study, with a male to female ratio of 1:18 
in the largest survey of 1262 children seen from 1981 to 1995 
in a children’s hospital in Australia. In adulthood, female 
psoriatic arthritis patients suffer greater disability than males, 
but gender differences in childhood have not been reported.9 
The only ethnic variance in psoriasis vulgaris that has been 
described is a reduction noted among Inuit people, suggesting 
that diets high in omega three fatty acids appears to have a 
preventive effect on psoriatic onset.10
Pathogenesis
The exact pathogenesis of psoriasis has not been completely 
elucidated; however, it is known to have a genetic basis, 
as 23.4% to 71% of children will have a family history of 
psoriasis3,8 and psoriasis is more common in identical than 
fraternal twins (65% to 72% vs 15% to 30%).11,12 HLA-Cw6 
has been known to be a susceptibility gene in psoriasis.12
It is understood that upper respiratory infections are a 
common cause of disease onset in childhood, with 14.8% 
having upper respiratory infections3,8 and 21.3% being 
pharyngeal culture positive for group A beta hemolytic 
streptococcus (Streptococcus pyogenes). The guttate psoriasis 
subset may have been linked to inflammatory focus in about 
two-thirds of cases, and is not caused by a specific subtype 
of group A beta hemolytic streptococcus, but rather by a 
host-specific response.2,13,14 Cross-reactivity of keratinocytes 
antigens with streptococcal antigens is thought to initiate 
psoriatic disease in this setting.15
Other infections that have been noted in psoriatic disease 
are presence of staphylococcal superantigens16 and HPV 
DNA.17
No single gene has been found to be responsible for 
psoriasis vulgaris. A series of genes have been isolated 
in which mutations have been associated with psoriatic 
disease, including IL12-B9 (1p31.3), IL-13 (5q31.1), IL-23R 
(1p31.3), HLABW6 PSORS6 STAT2/IL-23A (12q13.2), 
TNFAIP3 (6q23.3), and TNIP1 (5q33.1). These genes play 
a role in Th2 cell and Th17 cell activity as well as NF-κB 
signaling, demonstrating both a role for Th2 and Th17 
lymphocytes in the pathogenesis of psoriatic disease. Th17 
cells have been noted in psoriatic lesions, as have collections 
of Th2 and Th1 cells.12,18,19 Susceptibility loci for psoriasis 
may be shared with Crohn’s disease (IL-12B and IL-23R) 
and ulcerative colitis (IL-23R). As a result, patients with 
Crohn’s disease are 5 times more likely to develop psoriasis 
than other members of the population.12
Relationship to autoimmunity
Psoriasis is one of more than 80 autoimmune conditions that 
have been described. Autoimmunity encompasses a broad 
spectrum of medical diseases in which the body forms an 
immune reaction against a normal organ, the most common 
being thyroid disease. Physicians with an interest in learning 
about the broad spectrum of autoimmunity can access some 
information on the topic from the National Institutes of 
Health.20
Many patients with psoriasis will have other autoim-
mune conditions, often of the skin, including morphea21 and 
vitiligo vulgaris (sometimes this association is familial).22 
Family history of psoriasis and other forms of autoimmu-
nity can be noted in patients with psoriasis and in patients 
with a personal history of other autoimmune diseases 
such as multiple sclerosis.23 The concurrent incidence 
of autoimmune thyroiditis in adults has been reported in 
the literature to be variable, but there is no literature on 
co-morbid thyroid disease in pediatric psoriasis patients. 
One Italian study looking at adult patients with psoriatic 
arthritis (n = 80) and age-matched controls, demonstrating 
a greater incidence of thyroid disease in psoriatic arthritis 
patients, especially when the psoriatic arthritis patients 
had concomitant rheumatoid arthritis and in males with 
psoriatic arthritis.24 Other studies have not demonstrated 
significant increases of thyroiditis markers in adult patients 
with psoriasis vulgaris compared to age-matched controls.25 Therapeutics and Clinical Risk Management 2009:5 851
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Based on the conflicting data, annual thyroid screening 
has not been shown to be warranted in children; thyroid 
screening and screening for autoimmune thyroid disease 
should be performed in the setting of psoriatic arthritis, 
as there are some data to support an association of thy-
roiditis and psoriatic arthritis, and when psoriasis occurs in 
the presence of other autoimmune diseases such as vitiligo 
which have been associated which have a stronger associa-
tion with thyroid disease.26
Clinical characteristics 
and diagnosis (Table 1)
Psoriasis vulgaris occurs in a variety of clinical types, each of 
which is listed in Table 1. A few clinical features of psoriasis 
that are pertinent during physical examination include 1) the 
isomorphic response or Koebner phenomenon, which is 
occurrence of lesions in areas of trauma, 2) altered pigmenta-
tion with lesional clearance, 3) the Auspitz sign – pinpoint 
bleeding at the base of scale that has been removed, and 
4) presence of nail pitting, which can aid in diagnosis of 
the disease.27
Severity grading for psoriasis is usually based on surface 
area and presence and co-morbid psoriatic arthritis. The 
Psoriasis Area and Severity Index (PASI) can be used to 
assess severity (Table 2). Others will divide disease into mild 
if less than 3% body surface area, moderate 3% to 10% body 
surface area, and severe 10% body surface area.28
Differential diagnosis
The differential diagnosis of psoriasis includes other 
papulosquamous disorders of childhood including lichen 
planopilaris, psoriasiform ID reactions, nummular dermatitis, 
pityriasis rosea, and pityriasis rubra pilaris. Biopsy can 
be helpful in differentiating psoriasis from these other 
illnesses.
Treatments
The treatments of psoriasis have expanded over the past 
decade; however the use of topical therapy in childhood is 
the first line of treatment for skin-limited disease, in combi-
nation with a trial of oral antibiotics where indicated. With 
chronicity of illness and in more severe cases, systemic 
therapy and phototherapy are added to help induce remission. 
Significant psychological disturbances are seen in children 
with psoriasis, no matter what the surface area.29 Disease, 
although cutaneous, should be treated more aggressively 
when it is causing psychological disturbance, to improve 
quality of life.
Topical therapy
Topical  therapies  for  pediatric  psoriasis  include 
over-the-counter agents such as tar and salicylic acid, the 
latter of which aids in removal of hyperkeratosis. Tar has been 
a controversial medication in pediatric psoriasis, especially 
when combined with ultraviolet light in the Goeckermann 
regimen, because of demonstrable genotoxic risk, including 
chromosomal aberrations in peripheral lymphocytes and 
release of heat shock protein.30 Prescription agents for 
psoriasis vulgaris in childhood include anthralin,31 topical 
corticosteroids, topical calcipotriene with or without topical 
corticosteroids, and topical calcineurin inhibitors. Below the 
age of 12 years there have been no topical agents approved 
specifically by the FDA for treatment of psoriasis vulgaris 
in childhood. Off-label usage has been well described in 
the literature for childhood psoriatic disease, and all of the 
topical agents mentioned appear effective at times for pedi-
atric psoriasis. Formulations chosen and strengths should 
be determined based on patient age, PASI score, quality of 
life, and patient age.
Anthralin 1% or dithranol are rarely used for localized 
areas and can cause localized irritation.31 Topical clobetasol 
has been approved for use in children ages 12 and over in 
some formulations and can be quite effective for use in 
psoriatic lesions in adolescents, but runs a risk of atrophy 
because of class I status.32 In pediatric psoriasis topical 
corticosteroids are usually prescribed similarly to prescrip-
tions in atopic dermatitis of childhood. Low- to mid-potency 
corticosteroids, class 5–7, are chosen for facial and inter-
triginous lesions, while mid-potency class 2–4, are chosen 
for extremities and the scalp.33 Topical corticosteroids run 
a risk of local atrophy and systemic absorption, the latter 
becoming more likely if used for larger surface areas.Topical 
calcipotriene34 or calcitriol can be used for pediatric psoria-
sis, the latter being well tolerated for sensitive skin.35 Side 
effects are generally limited to local intolerance or irritation. 
Systemic absorption and alteration of calcium levels are a 
theoretical risk; however, they are unlikely if used on limited 
body surface area. Topical calcineurin inhibitors, tacrolimus 
0.3% ointment,36 and pimecrolimus 1% can be beneficial for 
pediatric psoriasis, particularly in sites where atrophy is of 
risk, such as the face, intertriginous areas, and groin. Use 
in children under the age of 2 years is not recommended 
by the FDA.
Phototherapy
Phototherapy is a safe and effective treatment for children 
old enough to stand still in a phototherapy booth, particularly Therapeutics and Clinical Risk Management 2009:5 852
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teenagers with extensive disease. Generalized or hand foot 
therapy, either narrowband UVB (NBUVB) or psoralens and 
UVA (PUVA), can be used. Topical psoralens are preferable 
to oral psoralens because of the difficulty of wearing protec-
tive eyewear for a 24-hour time period after oral psoralens. 
As PUVA has been associated with long-term carcinogenicity 
in psoriatics, NBUVB is likely safer in childhood cases.36–38
Systemic agents
Systemic agents should be saved for severe psoriasis, 
disabling psychological ramifications, and psoriatic arthritis. 
Usage of systemic agents is generally limited to a 6-month 
time period for immunosuppressants such as cyclosporine, 
acitretin or methotrexate. Longer usage periods have been 
observed to be safe in rheumatoid arthritis patients on 
etanercept, however usage beyond a one year time period has 
not been well assessed in pediatric psoriatics. Methotrexate 
has been used for pediatric patients for decades longer 
than etanercept. Oral antibiotics are the systemic therapy 
of choice in early disease, due to their superior side effect 
profile.
Oral antibiotics
Oral antibiotics can be useful in treating psoriasis vulgaris, 
particularly in the setting of positive oral pharyngeal cultures, 
presence of perianal bacterial dermatitis, pustular psoriasis,39 
or in guttate psoriasis of childhood (but not adult guttate 
disease), as these settings are linked to a bacterial precipitant 
of psoriasis.40 Use of oral antibiotics has demonstrated mixed 
results, many authors finding mixed results with use.41 Oral 
antibiotics are often used at first sign of psoriasis in children, 
but no placebo-controlled trials have compared antibiotics 
with placebo. Furthermore, the ideal regimen of antibiotic 
use is unknown.
Methotrexate
When pediatric psoriasis becomes chronic and severe 
(PASI  10), systemic therapy provides the major source 
of improvements in pediatric quality of life. The original 
psoriatic systemic therapy used for extensive psoriasis is 
methotrexate, which has been used for over 3 decades for 
pediatric psoriasis and pediatric psoriatic arthritis. Two 
recent publications have evaluated cohorts of pediatric 
psoriatic patients treated with methotrexate. Methotrexate 
(dosed at 0.2 to 0.7 mg/kg/week) provides excellent clear-
ance or PASI 75 (75% PASI reduction) in most children.42 
While monitoring blood counts and liver function tests are 
required, liver function alteration is rarely observed and 
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seems to be most associated with obesity and consequent 
fatty liver changes.43,44 Methotrexate also has the advantage 
over cyclosporine in clearing or improving psoriatic arthritis. 
Therapy is started with a small dosage (7.5 mg) followed 
by escalating dosages while sequentially monitoring labs.42 
Addition of folic acid supplementation helps protect against 
pancytopenia and macrocytic anemia.45
Cyclosporine A
Cyclosporine A, a systemic immunosuppressant used 
originally for prevention of transplant rejection, can be 
dosed for oral use at 3 to 5 mg/kg can improve cutaneous 
symptomatology in pediatric psoriatic patients. Alterations in 
renal function with altered serum urea nitrogen and creatinine 
and high blood pressure can be observed. Therefore, 
close monitoring is warranted. Risks of malignancy and 
lymphoproliferative disorders seem to be minimal in children 
treated for skin diseases due to limited courses of therapy 
and dosages that are below 5 mg/kg/day.42,46
Retinoids
Acitretin orally 0.5 to 1 mg/kg per day has been used for 
disorders of cornification and psoriasis with good results. 
Because of teratogenicity, oral contraceptives in girls of 
childbearing age should be used concurrently, and for 3 years 
after drug disocontinuation. Short-term side effects, such as 
elevations in lipids or alterations in blood counts, require 
monitoring. Long-term changes such as bony abnormalities 
can occur and treatment periods should be limited, using a 
cyclic approach. Bony evaluation may be required.42
Biologics
Etanercept and infliximab, injectable and intravenous, 
respectively, tumor necrosis factor alpha (TNF-α) inhibitor 
therapies have been used for a decade in pediatric autoim-
mune diseases including rheumatoid arthritis,47 TNF-α 
receptor 1-associated periodic syndrome without fever 
(TRAPS),48 juvenile idiopathic arthritis,49 and Crohn’s 
disease. Safety and efficacy data are available for up to 
8 years’ use in juvenile rheumatoid arthritis. Long-term 
use did not increase serious side effects. An ACR 70 
was achieved by most children treated, with no cases of 
tuberculosis, opportunistic infections, malignancies, lym-
phomas, lupus, demyelinating disorders, or death. Long-term 
improvements on bony disease in arthritis of childhood have 
been demonstrated with etanercept.50
A recent clinical trial described the results of a phase II 
clinical trial of etanercept in 211 pediatric psoriatics aged 
4 to 17 years using a 12-week, double-blind treatment 
phase, with a 24-week open-label phase. At week 12, 57% of 
patients achieved a PASI 75 compared with 11% of placebo-
treated patients (P  0.001) and a PASI 90 was achieved in 
27% of patients compared with 7% of placebo. Clearance 
was lost in 29 of 69 patients who withdrew in weeks 36 to 
48 weeks. Four serious adverse events including 3 serious 
infections in children treated with open-label phase, all of 
which resolved.51 These data significantly expand upon prior 
anecdotal data describing efficacy of etanercept for pediatric 
psoriasis.52 Anecdotal report of a single case that failed 
etanercept responding to infliximab, suggests this may be 
an alternative therapy in etanercept-resistant cases.53
Natural supplements
A common question asked by parents of children with 
psoriasis is “What dietary changes or natural supplements can 
I give my child to improve their skin disease?” While natural 
supplements or dietary alterations cannot cure psoriasis, they 
can improve disease severity. The best-known supplement is 
fish oil, rich in omega-3 fatty acids. The ingestion of this agent 
for psoriasis is based upon its preventive effects in the Inuit 
population. Oral and intravenous supplementation of omega-3 
and, less effectively, omega-6 fatty acids54 have been found 
effective in psoriatic adults, possibly through alterations in 
production and alterations in arachidonic acid (20:4 omega 6) 
and docosapentaenoic acid.55 Fish meals 4 to 6 times per week 
can mimic the effects of omega-3 supplementation.56
Indigo naturalis, a traditional Chinese medicine, can be 
formulated into topical ointment with anecdotal reports of good 
results in childhood psoriasis when used for 8 weeks.57
Table 2 Psoriasis Area and Severity index (PASi) score
To determine PASi score, establish grade and severity and then use 
site-based weighting
Grade: surface area as below (0–6)
0% of involved area, grade: 0
•  10% of involved area, grade: 1
•  10%–29% of involved area, grade: 2
•  30%–49% of involved area, grade: 3
•  50%–69% of involved area, grade: 4
•  70%–89% of involved area, grade: 5
•  90%–100% of involved area, grade: 6
Severity: 0–4 none to severe
erythema (redness)
induration (thickness)
Desquamation (scaling)
Notes:    The sum of all three severity parameters is than calculated for each section of 
skin, multiplied by the area score for that area and multiplied by weight of respective 
section (0.1 for head, 0.2 for arms, 0.3 for body and 0.4 for legs).Therapeutics and Clinical Risk Management 2009:5 855
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Conclusions
Recent advances in genetics and the unraveling of the 
processes responsible for psoriatic disease are making pos-
sible considerable advancements in the treatment of pediatric 
psoriasis.
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